vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737 [Yahoo! Finance]
vTv Therapeutics Inc. - Class A (VTVT)
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vtvtherapeutics.com
Company Research
Source: Yahoo! Finance
vTv Therapeutics Inc. (NASDAQ: VTVT ) is one of the most promising micro-cap stocks according to analysts . On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., transforming a regional agreement into a global collaboration for the development of HPP737. Under the amended terms, Newsoara gains exclusive worldwide rights to develop and commercialize this novel PDE4 inhibitor. In exchange, vTv Therapeutics will receive an immediate $20 million upfront payment, with the potential for an additional $115 million in future development and sales milestones, plus tiered royalties on net sales. HPP737 is a selective oral therapy designed to treat inflammation-mediated diseases, such as psoriasis, by inhibiting interleukin-23 and tumor necrosis factor alpha. While traditional PDE4 inhibitors are often limited by gastrointestinal side effects like nausea and vomiting, early clinical data suggest that HPP737 is well-tolerated and may avoid these common comp
Show less
Read more
Impact Snapshot
Event Time:
VTVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTVT alerts
High impacting vTv Therapeutics Inc. - Class A news events
Weekly update
A roundup of the hottest topics
VTVT
News
- VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst [Seeking Alpha]Seeking Alpha
- vTv Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- vTv Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737GlobeNewswire
- vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock, up previously from $40.00.MarketBeat
VTVT
Earnings
- 5/15/25 - Miss
VTVT
Sec Filings
- 2/26/26 - Form 8-K
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- VTVT's page on the SEC website